Evidence map›Paper›PMID 41783115›Full record

ReviewFrontiers in digital health2026

Real-world walking speed as a digital biomarker and outcome measure for clinical trials-a systematic review, regulatory status and future directions.

Margaux Poleur, Cyril Tychon, Stephen Gilbert, Martin Daumer, Laurent Servais

Abstract readReview
In one paragraph

Review in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Margaux PoleurUniversity Department of Neurology, Citadelle Hospital, Liège, Belgium.
Cyril TychonDepartment of Pediatrics, University of Liège, Liège, Belgium.
Stephen GilbertElse Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany.
Martin Daumer *SLCMSR E.V. - The Human Motion Institute, Munich, Germany.
Laurent Servais *Department of Paediatrics, MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Walking speed is a key measure of health and mobility across a wide range of diseases. Traditional gait assessments in clinical settings may not accurately reflect real-world mobility patterns. Wearable sensors offer an ecologically valid alternative by capturing every movement in daily life, but there are few robust, validated reports. We aimed to identify evidence on real-world gait speed measurements that have received or are seeking regulatory approval from agencies such as the European Medicines Agency and the U.S. Food and Drug Administration. Method: We conducted a systematic review following a comprehensive search strategy using the Ovid platform, guided by pre-defined selection criteria and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We also manually searched the websites of key regulatory agencies and the ClinicalTrials.gov database. Results: Our search identified 503 records, of which 10 met the inclusion criteria. Most studies were part of large-scale initiatives, including the qualification of the Stride Velocity 95th Centile and the MOBILISE-D project. No device or outcome measure that assesses walking speed in real-world conditions has been fully validated by the FDA. We found four letters of intent on the FDA website related to this concept. One outcome, the 95th centile of stride velocity, has been approved by the EMA as a primary endpoint for assessing ambulant patients with Duchenne Muscular Dystrophy. Conclusion: Despite the potential of wearable devices to enhance drug development and clinical decision-making, real-world walking speed remains insufficiently validated across most conditions because data is missing. The widespread adoption of digital outcomes to assess ambulation will require extensive validation efforts, regulatory pathway adaptations, and improved standardization of devices, algorithms, and study methodologies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633578, PROSPERO CRD42025633578.

Indexed as

digital healthoutcome measurereal-worldregulatory approvalwalking speed

Identifiers

PMID41783115
PMCPMC12954611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.